Q-Line BiotechNSE:QLINE -5.15%12 Return-on-Tangible-Equity is 17.42% as of Mar. 2025, which is 28% below its 10-year median of 24.26. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 80.34% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Q-Line Biotech's annualized net income for the quarter that ended in Mar. 2025 was ₹281 Mil. Q-Line Biotech's average shareholder tangible equity for the quarter that ended in Mar. 2025 was ₹1,615 Mil. Therefore, Q-Line Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was 17.42%.
The historical rank and industry rank for Q-Line Biotech's Return-on-Tangible-Equity or its related term are showing as below:
NSE:QLINE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 17.42 Med: 24.26 Max: 25.22
Current: 17.42
During the past 3 years, Q-Line Biotech's highest Return-on-Tangible-Equity was 25.22%. The lowest was 17.42%. And the median was 24.26%.
NSE:QLINE's Return-on-Tangible-Equity is ranked better than 80.34% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs NSE:QLINE: 17.42
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Q-Line Biotech Return-on-Tangible-Equity Related Terms
Q-Line Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Return-on-Tangible-Equity Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Return-on-Tangible-Equity
25.22
24.26
17.42
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Return-on-Tangible-Equity
25.22
24.26
17.42
NSE:QLINE vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Q-Line Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.42% mean?
Q-Line Biotech (NSE:QLINE) has a Return-on-Tangible-Equity of 17.42% as of Mar. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Q-Line Biotech and its competitors. This is 28% below median its historical median of 24.26. Over the past decade, Q-Line Biotech's Return-on-Tangible-Equity has ranged from 17.42 to 25.22. According to the industry distribution chart, Q-Line Biotech ranks #149 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 19.7%.
Is Q-Line Biotech's Return-on-Tangible-Equity too high?
Q-Line Biotech's current Return-on-Tangible-Equity of 17.42% is 28% below median its 10-year median of 24.26. Over the past 10 years, this metric has ranged from a low of 17.42 to a high of 25.22. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Q-Line Biotech's value of 17.42% is 327% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #149 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #149 out of 758 companies for Return-on-Tangible-Equity. This places Q-Line Biotech in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.08. Q-Line Biotech's value of 17.42% is 327% above this benchmark. Historically, Q-Line Biotech's own Return-on-Tangible-Equity has ranged from 17.42 to 25.22 over the past decade. While the company's 10-year median is 24.26 vs. the industry median of 4.08, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Return-on-Tangible-Equity of 17.42% is 327% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Return-on-Tangible-Equity is 17.42%, which is 28% below median its own 10-year median of 24.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Return-on-Tangible-Equity of 17.42%. The current Return-on-Tangible-Equity is 17.42%, which is 28% below median its 10-year median of 24.26 and 327% above the Medical Devices & Instruments industry median of 4.08. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Return-on-Tangible-Equity is 17.42% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 